-
Infigratinib is an
kinase inhibitor in
development for the
treatment of
achondroplasia and hypochondroplasia.
Infigratinib targets the
fibroblast growth...
-
Trafermin Antibodies:
Aprutumab Aprutumab ixadotin Kinase inhibitors:
Infigratinib FGFR3 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib...
-
Trafermin Antibodies:
Aprutumab Aprutumab ixadotin Kinase inhibitors:
Infigratinib FGFR3 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib...
-
Trafermin Antibodies:
Aprutumab Aprutumab ixadotin Kinase inhibitors:
Infigratinib FGFR3 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib...
-
Trafermin Antibodies:
Aprutumab Aprutumab ixadotin Kinase inhibitors:
Infigratinib FGFR3 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib...
-
Trafermin Antibodies:
Aprutumab Aprutumab ixadotin Kinase inhibitors:
Infigratinib FGFR3 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib...
-
Trafermin Antibodies:
Aprutumab Aprutumab ixadotin Kinase inhibitors:
Infigratinib FGFR3 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib...
- RET inhibitors:
Entrectinib (ALK, ROS1, NTRK), ****ibatinib (FGFR2),
Infigratinib,
Larotrectinib (NTRK),
Pemigatinib (FGFR), Pralsetinib, Repotrectinib...
-
cholangiocarcinoma appear to show
improved survival, but
numbers are small.
Infigratinib (Truseltiq) is a
tyrosine kinase inhibitor of
fibroblast growth factor...
-
Trafermin Antibodies:
Aprutumab Aprutumab ixadotin Kinase inhibitors:
Infigratinib FGFR3 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib...
